267 related articles for article (PubMed ID: 17429629)
1. Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer.
El-Rayes BF; Zalupski MM; Manza SG; Rusin B; Ferris AM; Vaishampayan U; Heilbrun LK; Venkatramanamoorthy R; Shields AF; Philip PA
Cancer Chemother Pharmacol; 2008 Feb; 61(2):283-9. PubMed ID: 17429629
[TBL] [Abstract][Full Text] [Related]
2. Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015.
Köhne CH; De Greve J; Hartmann JT; Lang I; Vergauwe P; Becker K; Braumann D; Joosens E; Müller L; Janssens J; Bokemeyer C; Reimer P; Link H; Späth-Schwalbe E; Wilke HJ; Bleiberg H; Van Den Brande J; Debois M; Bethe U; Van Cutsem E
Ann Oncol; 2008 May; 19(5):920-6. PubMed ID: 18065406
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer.
Kato T; Mishima H; Ikenaga M; Murata K; Ishida H; Fukunaga M; Ota H; Tominaga S; Ohnishi T; Amano M; Ikeda K; Ikeda M; Sekimoto M; Sakamoto J; Monden M
Cancer Chemother Pharmacol; 2008 Feb; 61(2):275-81. PubMed ID: 17429630
[TBL] [Abstract][Full Text] [Related]
4. Multicenter phase II study of oral capecitabine plus irinotecan as first-line chemotherapy in advanced colorectal cancer: a Korean Cancer Study Group trial.
Kim TW; Kang WK; Chang HM; Park JO; Ryoo BY; Ahn JS; Zang DY; Lee KH; Kang YK; Kim SR; Kim HK;
Acta Oncol; 2005; 44(3):230-5. PubMed ID: 16076694
[TBL] [Abstract][Full Text] [Related]
5. Results of a phase II trial of cetuximab plus capecitabine/irinotecan as first-line therapy for patients with advanced and/or metastatic colorectal cancer.
Cartwright T; Kuefler P; Cohn A; Hyman W; Berger M; Richards D; Vukelja S; Nugent JE; Ruxer RL; Boehm KA; Asmar L
Clin Colorectal Cancer; 2008 Nov; 7(6):390-7. PubMed ID: 19036692
[TBL] [Abstract][Full Text] [Related]
6. A phase I study of capecitabine, irinotecan, celecoxib, and radiation as neoadjuvant therapy of patients with locally advanced rectal cancer.
Malik I; Hussein F; Bush D; Alqaisi M; Bernal P; Byrd J; Garberoglio C
Am J Clin Oncol; 2010 Jun; 33(3):242-5. PubMed ID: 19806036
[TBL] [Abstract][Full Text] [Related]
7. The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer.
Shin SJ; Ahn JB; Choi HJ; Cho BC; Jeung HC; Rha SY; Chung HC; Roh JK
Cancer Chemother Pharmacol; 2008 Jan; 61(1):75-81. PubMed ID: 17375304
[TBL] [Abstract][Full Text] [Related]
8. Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study.
Jackson NA; Barrueco J; Soufi-Mahjoubi R; Marshall J; Mitchell E; Zhang X; Meyerhardt J
Cancer; 2009 Jun; 115(12):2617-29. PubMed ID: 19382200
[TBL] [Abstract][Full Text] [Related]
9. Irinotecan and capecitabine as second-line treatment after failure for first-line infusional 24-h 5-fluorouracil/folinic acid in advanced colorectal cancer: a phase II study.
Hofheinz RD; Gnad-Vogt U; Wein A; Saussele S; Kreil S; Pilz L; Hehlmann R; Hochhaus A
Anticancer Drugs; 2005 Jan; 16(1):39-45. PubMed ID: 15613902
[TBL] [Abstract][Full Text] [Related]
10. Multicenter phase II study of fixed sequences of capecitabine combined with oxaliplatin or irinotecan in patients with previously untreated metastatic colorectal cancer.
Cassinello J; Alvarez JV; López MJ; Pujol E; Colmenarejo A; Segovia F; Marcos F; Filipovich E; Arcediano A; Castro IG
Clin Colorectal Cancer; 2006 Mar; 5(6):429-35. PubMed ID: 16635282
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancer.
Renouf DJ; Welch S; Moore MJ; Krzyzanowska MK; Knox J; Feld R; Liu G; MacKay H; Petronis J; Wang L; Chen E
Cancer Chemother Pharmacol; 2012 May; 69(5):1339-44. PubMed ID: 22349811
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of capecitabine and oxaliplatin combination as second-line treatment in advanced colorectal cancer.
Heras P; Kritikos K; Hatzopoulos A; Xourafas V; Kritikos N; Karagiannis S; Mitsibounas D
Am J Ther; 2009; 16(4):319-22. PubMed ID: 19352139
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of biweekly dose-intensified oral capecitabine plus irinotecan (bXELIRI) for patients with advanced or metastatic gastric cancer.
Oh SC; Sur HY; Sung HJ; Choi IK; Park SS; Seo JH; Jeen YT; Chun HJ; Shin SW; Mok YJ; Kim JS; Kim YH
Br J Cancer; 2007 May; 96(10):1514-9. PubMed ID: 17473829
[TBL] [Abstract][Full Text] [Related]
14. A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity.
Borner MM; Bernhard J; Dietrich D; Popescu R; Wernli M; Saletti P; Rauch D; Herrmann R; Koeberle D; Honegger H; Brauchli P; Lanz D; Roth AD;
Ann Oncol; 2005 Feb; 16(2):282-8. PubMed ID: 15668285
[TBL] [Abstract][Full Text] [Related]
15. Short-time infusion of oxaliplatin in combination with capecitabine (XELOX30) as second-line therapy in patients with advanced colorectal cancer after failure to irinotecan and 5-fluorouracil.
Pfeiffer P; Sørbye H; Ehrsson H; Fokstuen T; Mortensen JP; Baltesgard L; Tveit KM; Øgreid D; Starkhammar H; Wallin I; Qvortrup C; Glimelius B
Ann Oncol; 2006 Feb; 17(2):252-8. PubMed ID: 16291583
[TBL] [Abstract][Full Text] [Related]
16. A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy.
Shin SJ; Ahn JB; Park KS; Lee YJ; Hong YS; Kim TW; Kim HR; Rha SY; Roh JK; Kim DH; Kim C; Chung HC
Invest New Drugs; 2012 Apr; 30(2):672-80. PubMed ID: 21188464
[TBL] [Abstract][Full Text] [Related]
17. Celecoxib and mucosal protection: translation from an animal model to a phase I clinical trial of celecoxib, irinotecan, and 5-fluorouracil.
Javle MM; Cao S; Durrani FA; Pendyala L; Lawrence DD; Smith PF; Creaven PJ; Noel DC; Iyer RV; Rustum YM
Clin Cancer Res; 2007 Feb; 13(3):965-71. PubMed ID: 17289892
[TBL] [Abstract][Full Text] [Related]
18. Irinotecan plus capecitabine as first-line chemotherapy in advanced colorectal cancer.
Gennatas C; Michalaki V; Gennatas S; Papalambros E
Anticancer Res; 2008; 28(3B):1923-6. PubMed ID: 18630482
[TBL] [Abstract][Full Text] [Related]
19. Results of a phase II open-label study of capecitabine in combination with irinotecan as first-line treatment for metastatic colorectal cancer.
Cartwright T; Lopez T; Vukelja SJ; Encarnacion C; Boehm KA; Asmar L
Clin Colorectal Cancer; 2005 May; 5(1):50-6. PubMed ID: 15929806
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer.
El-Rayes BF; Zalupski MM; Shields AF; Ferris AM; Vaishampayan U; Heilbrun LK; Venkatramanamoorthy R; Adsay V; Philip PA
Invest New Drugs; 2005 Dec; 23(6):583-90. PubMed ID: 16034525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
